依普利酮国内入医保没？

(Eplerenone, Inspra) is a selective aldosterone receptor antagonist. There are tablets on the market, eplerenone tablets (25mg, 50mg). Eplerenone is approved for 1. Congestive heart failure after acute myocardial infarction: Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for congestive heart failure after acute myocardial infarction. 2. Anti-hypertension: Eplerenone can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension.

Eplerenone (Inspra) usage and dosage: 1. Congestive heart failure after acute myocardial infarction: The recommended dose is 50 mg/time, once/day. The initial dose should be 25 mg/time, once/day, and within 4 weeks, the dose should be gradually increased to 50 mg/time, once/day if the patient tolerates it. 2. Anti-hypertensive: Eplerenone can be used alone or in combination with other anti-hypertensive drugs. The recommended initial dose for use alone is 50mg/time, once/day. Obvious pressure-reducing effect will appear within four weeks of taking the medicine. If the pressure effect is not obvious, it can be increased to 50mg/time, 2 times/day. Higher dosages are not recommended, otherwise there is an increased risk of adverse reactions such as hyperkalemia.

It is understood that eplerenone is not currently on the market in China, so eplerenone is not sold in China, so eplerenone has not yet entered domestic medical insurance. At present, the Indian version of eplerenone is the one most used by domestic patients. The Indian version of eplerenone is produced by Lupine Pharmaceuticals of India. The specification is 50mg*100 tablets and the price is equivalent to RMB 500. The price is relatively cheap, which allows most patients at home and abroad to reduce their financial burden.